13 results on '"Vehling-Kaiser U"'
Search Results
2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306.
3. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
4. Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
5. Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).
6. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine: Interim toxicity analysis of a multicenter, randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
7. Weekly versus 3-weekly docetaxel (D2) plus doxorubicin (D4) for first-line treatment of metastatic breast cancer (MBC)
8. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group
9. Oral and intravenous vinorelbine plus trastuzumab for 1st-line treatment of HER2-overexpressing metastatic breast cancer (MBC). A trial of the german AIO breast cancer group
10. Evaluation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial
11. Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group
12. Gemcitabine plus carboplatin for patients with pretreated, metastatic breast cancer: A phase II trial
13. Oxaliplatin plus 5FU/folinic acid (FUFOX Regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenter Phase II STOMOX Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.